George D. Yancopoulos - 22 Dec 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
President and Chief Scientific, Director
Signature
/s/**George D. Yancopoulos
Issuer symbol
REGN
Transactions as of
22 Dec 2021
Net transactions value
-$91,395,761
Form type
4
Filing time
23 Dec 2021, 15:29:47 UTC
Previous filing
17 Aug 2021
Next filing
08 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $42,823,355 +239,063 +27% $179.13 1,126,546 22 Dec 2021 Direct
transaction REGN Common Stock Tax liability $97,554,547 -159,915 -14% $610.04 966,631 22 Dec 2021 Direct
transaction REGN Common Stock Options Exercise $54,952,458 +203,204 +21% $270.43 1,169,835 22 Dec 2021 Direct
transaction REGN Common Stock Tax liability $91,617,027 -150,182 -13% $610.04 1,019,653 22 Dec 2021 Direct
holding REGN Common Stock 5,848 22 Dec 2021 By 401(k) Plan
holding REGN Common Stock 213,693 22 Dec 2021 By Trust for Chldn. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -239,063 -100% $0.000000* 0 22 Dec 2021 Common Stock 239,063 $179.13 Direct F2
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -203,204 -100% $0.000000* 0 22 Dec 2021 Common Stock 203,204 $270.43 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As investment trustee of trusts for the benefit of the reporting person's children.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.